Insider Buying: Telix Pharmaceuticals (NASDAQ:TLX) CEO Acquires $497,178.45 in Stock

Telix Pharmaceuticals Limited (NASDAQ:TLX) CEO Christian Behrenbruch bought 33,435 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The shares were acquired at an average price of $14.87 per share, for a total transaction of $497,178.45. Following the completion of the transaction, the chief executive officer owned 20,742,935 shares in the company, valued at $308,447,443.45. This represents a 0.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Christian Behrenbruch also recently made the following trade(s):

• On Tuesday, April 28th, Christian Behrenbruch bought 34,500 shares of Telix Pharmaceuticals stock. The shares were acquired at an average price of $14.48 per share, for a total transaction of $499,560.00.

Telix Pharmaceuticals Price Performance

Shares of Telix Pharmaceuticals stock opened at $10.68 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The firm’s 50-day simple moving average is $9.18 and its 200-day simple moving average is $8.77. Telix Pharmaceuticals Limited has a twelve month low of $6.28 and a twelve month high of $18.49.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to analyst estimates of $421.50 million. Equities analysts forecast that Telix Pharmaceuticals Limited will post 0.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the last quarter. XTX Topco Ltd bought a new position in Telix Pharmaceuticals during the 4th quarter valued at about $89,000. OLD Mission Capital LLC bought a new position in Telix Pharmaceuticals during the 4th quarter valued at about $111,000. Vident Advisory LLC bought a new position in Telix Pharmaceuticals during the 4th quarter valued at about $204,000. Finally, IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $213,000.

Analysts Set New Price Targets

TLX has been the topic of several recent research reports. Citigroup lifted their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.13.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.